MV 0633
Latest Information Update: 19 Nov 2010
At a glance
- Originator Miravant Medical Technologies
- Class Cardiovascular therapies
- Mechanism of Action Photosensitisers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Atherosclerosis; Coronary artery restenosis; Vascular restenosis
Most Recent Events
- 19 Nov 2010 Discontinued - Preclinical for Atherosclerosis in USA (unspecified route)
- 19 Nov 2010 Discontinued - Preclinical for Coronary artery restenosis in USA (Intracoronary)
- 19 Nov 2010 Discontinued - Preclinical for Vascular restenosis in USA (unspecified route)